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A B S T R A C T
Introduction: Calcium has a pivotal role in haemostasis. We investigated the association of baseline calcium
levels with admission intracerebral haemorrhage (ICH) volume.
Methods: This is a retrospective analysis of consecutive ICH patients in an academic hospital between January
2005 and March 2010. Computed tomography (CT) of the brain and serum/plasma ionized calcium had to be
taken within 72 h of symptom onset and within 12 h of each other in order to fulfil the study criteria. ICH cases
related to trauma or tumour as well as sole intraventricular haemorrhages were excluded. Baseline haematoma
volumes were calculated using semiautomated planimetry. The hypocalcaemic (Ca-ion< 1.16mmol/L) and
normocalcaemic (1.16–1.30mmol/L) patient groups were compared in univariate analyses. Association between
admission hypocalcaemia and haematoma volume was studied using multivariable regression models.
Results: Out of 1013 consecutive patients, 447 fulfilled the study criteria. Hypocalcaemic patients (n=178;
39.8%) had larger baseline hematoma volumes (median 30.2mL, IQR 11.4–58.7 mL), compared to normo-
calcaemic patients (n= 255; 57.0%; median 16.8 mL, IQR 7.4–44.2mL). The median ICH volume among hy-
percalcaemic patients (n= 14; 3.1% of included patients) was 6.5mL (IQR 3.1–34.6mL). On linear regression,
admission hypocalcaemia was independently associated with larger hematoma volumes (β=11.77; 95% CI
4.66–18.87, P= 0.01). Patients with larger haematoma volumes had higher mortality.
Conclusion: Hypocalcaemia is associated with larger admission haematoma volumes among ICH patients. Higher
mortality among hypocalcaemic patients is very likely mediated through larger ICH volumes.
1. Introduction
Intracerebral haemorrhage (ICH) results from rupture of an in-
tracerebral artery and causes approximately 10–15% of all strokes. It is
a devastating condition with early mortality rates approaching 40%,
and many survivors remaining disabled [1]. There is currently no ef-
fective acute intervention for ICH, and treatment is mostly supportive.
Known predictors for ICH mortality include older age, lower baseline
Glasgow Coma Scale (GCS), higher National Institutes of Health Stroke
Scale (NIHSS) score, infratentorial location, ICH and intraventricular
haemorrhage (IVH) volumes and their growth, oedema, hypergly-
caemia, hydrocephalus, herniation, anticoagulation, and multiple hae-
morrhages [2–7]. Higher NIHSS score predicts worse functional
outcome [8], and greater functional dependence among ICH survivors
has been associated with age, GCS, baseline ICH volume, change of ICH
volume at 24 h, and IVH [9].
Factors participating in haemostasis and the coagulation cascade
have a substantial effect on the prognosis of patients with ICH [10]. The
coagulation system includes cellular elements, such as platelets, and the
proteins of the coagulation and fibrinolytic pathways. Primary hae-
mostasis involves platelets' adhesion to endothelial proteins, and is
followed by secondary haemostasis, i.e. aggregation of platelets and
fibrin formation [11]. In the context of an injured vessel wall causing
ICH, platelets adhere to the extracellular matrix, become activated, and
form a plug to prevent further bleeding. Several platelet activation
agonists, such as subendothelial collagen, thromboxane A2, adenosine
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diphosphate (ADP) released from the activated platelets, and thrombin
generated as a result of the coagulation cascade, trigger signalling
pathways that lead to a rise in intracellular Ca2+. The cytosolic calcium
derives both from intracellular stores and extracellular sources through
the plasma membrane. The elevation of the cytosolic calcium results in
further platelet activation and clot formation [12,13]. Calcium is also
an important mediator of extracellular coagulation cascade by acti-
vating several coagulation factors, such as Factors IX and X to their
active forms, and prothrombin to thrombin [14].
Approximately 50% of the serum calcium is in its active ionized
form, and the rest is combined to albumin or other complexes. The main
factors regulating the calcium levels are parathyroid hormone, vitamin
D, and fibroblast growth factor FGF-23. A number of conditions can
lead to hypocalcaemia, including hypoparathyroidism, resistance to
parathyroid hormone (PTH), and disorders in vitamin D metabolism
and action [15].
Calcium may contribute to ICH volume and outcome through its
effect on the coagulation cascade. Studies that have analysed the as-
sociation between ICH volume and serum calcium levels reported an
association between hypocalcaemia and larger ICH volumes, severity of
symptoms (n=273) [16], and ICH expansion (n= 2103; for ICH ex-
pansion n= 1393) [17]. Moreover, one study showed elevated calcium
levels to be associated with better outcomes (n= 365) [18].
Our aim was to examine the association of hypocalcaemia with
admission haematoma volume in a large consecutive cohort of non-




This is a retrospective analysis of the Helsinki ICH study consisting
of 1013 consecutive ICH patients treated at Helsinki University Hospital
between January 2005 and March 2010. The methodology and details
of this study have been reported elsewhere [10]. Briefly, this cohort
includes all consecutive adult ICH patients presenting at the neurology
emergency department between January 2005 and March 2010. All
underlying causes (including hypertension, anticoagulation, and amy-
loid angiopathy) of ICH were determined using the SMASH-U classifi-
cation system [10,19]. Patients with ICH from trauma or tumour were
excluded. Information on comorbidities, medication and clinical status
on admission were obtained from medical records. The severity of the
symptoms was assessed using the National Institutes of Health Stroke
Scale (NIHSS) and the Glasgow Coma Scale (GCS). Warfarin was the
only oral anticoagulant in our cohort. All-cause mortality data was
retrieved from national Population Registry Centre last updated in
November 2014, which is a reliable source of mortality in Finland,
while foreign residents are lost to follow-up.
Patients were included in the present analysis if they had a) ionized
plasma/serum calcium taken within 72 h of symptom onset, b) admis-
sion CT of the brain taken within 72 h of symptom onset, and c) the two
taken within 12 h of each other. When symptom onset time was un-
known, we used the last-known-well time as the onset time. We ex-
cluded patients with pure intraventricular haemorrhage (n=5).
Volume of the ICH was measured by semi-automatic planimetry using
Analyze 12.0 software [6,20]. Hypocalcaemia was defined as Ca-
ion<1.16mmol/L, normocalcaemia Ca-ion 1.16–1.30mmol/L, and
hypercalcaemia as above 1.30mmol/L according to our laboratory re-
ference range, and pH adjusted values were used.
This study has been approved by the institutional review board as
an observational registry study with no study-related patient contact.
Therefore, no patient consent was required.
2.2. Statistical analysis
We expressed categorical variables as counts (%), and continuous
variables as mean (SE) or median (IQR) values after testing for normal
distribution. The differences between hypo- and normocalcaemic pa-
tients were calculated using the χ2 test, the t-test, or the Mann-Whitney
U test as appropriate.
We analysed the association between admission calcium level and
baseline ICH volume using multivariable linear regression model. The
variables with P < 0.1 in the univariate linear regression model
(supplemental Table A.2, online only) were included as covariates in
the multivariable analysis. Hypocalcaemia was studied as a dichot-
omous variable; other laboratory test values were not included in the
analyses. The time-points for plasma/serum calcium levels were strictly
defined as per the study criteria (see above) and all other laboratory test
results come from the admission values. Including all laboratory para-
meters as per the same criteria as were set for calcium would inevitably
lead to a major drop in n-number. For these reasons, we included only
calcium levels into the analyses.
For the secondary analysis, we used binary logistic regression to
study the associations of 90-day mortality and hypocalcaemia. As pre-
dictors for mortality are well known, we adjusted our comparison
analysis (between hypo- and normocalcaemic patients) for known
predictors of mortality (ICH and IVH volume, age, oral anticoagulation,
infratentorial location of ICH, and multiple haemorrhages on imaging).
NIHSS and GCS are dependent on ICH/IVH volume (collinearity), and
were not analysed separately. We tested NIHSS and GCS separately in
the same model, and they both had a similar significant association
with mortality. The results of the other variables were also similar in
those models. Prior medications, infratentorial location, multiple hae-
morrhages, and hypocalcaemia were included in the models as cate-
gorical variables, and age, ICH volume, and IVH volume were included
as continuous variables.
As hypercalcaemic patients were few (n= 14), we only report their
ICH volumes; they were excluded from other analyses. Statistical ana-
lyses were made using SPSS v.22 (IBM, Armonk, NY). A two-sided
probability (P) value< 0.05 was considered significant.
3. Results
Of the 1013 patients in our database, 447 met the inclusion criteria
(Fig. 1).
Supplementary Table A.1 (online only) compares basic character-
istics between patients included and excluded in the study. Of included
patients, 178 (39.8%) had hypocalcaemia, and 255 (57.0%) were nor-
mocalcaemic. The median ICH volume among hypercalcaemic patients
(n= 14 [3.1%]) was 6.5 mL (IQR 3.1–34.6 mL). The comparisons of the
baseline characteristics, laboratory values, radiological parameters and
outcome parameters between hypocalcaemic and normocalcaemic pa-
tients are shown in Table 1.
Compared with normocalcaemic patients, hypocalcaemic patients
had larger ICH (30.2 mL, IQR 11.4–58.7mL vs. 16.8 mL, IQR
7.4–44.2 mL; P < 0.001) and IVH volumes (2.9 mL, IQR 0.0–22.5mL
vs. 0.0mL, IQR 0.0–8.7mL; P < 0.001). The hypocalcaemic patients
were more often male (66.9% vs. 56.9%; P= 0.04), less frequently
dyslipidaemic (13.3% vs. 21.7%; P=0.03), had higher admission
NIHSS scores (19.0, IQR 10.0–34.0 vs. 12.0, IQR 6.0–21.0; P < 0.001)
and lower GCS scores (10.0, IQR 4.0–14.0 vs. 14.0, IQR 10.0–15.0;
P < 0.001), had higher white cell count (9.7, IQR 7.2–12.0 vs. 8.0, IQR
6.4–10.4; P < 0.001), C-reactive protein (CRP) (5.0, IQR 3.0–7.0 vs.
4.0, IQR 3.0–6.0; P= 0.017), and glucose on admission or in ambu-
lance (8.4, IQR 6.9–10.8 vs. 7.5, IQR 6.3–9.5; P < 0.001), and lower
potassium (3.7, IQR 3.3–4.0 vs. 3.8, IQR 3.5–4.1; P=0.018), and so-
dium (137.0, IQR 135.0–139.0 vs. 138.0, IQR 136.0–140.0, P= 0.046)
values along with lower creatinine values (63.0, IQR 54.0–82.5 vs.
69.0, IQR 58.0–85.8; P=0.040). Hydrocephalus was more common
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among hypocalcaemic patients (30.9% vs. 12.2%; P < 0.001), but was
not included in the analyses or tables. There was no difference between
the rate of ventricular drainage in the two groups (hypocalcaemic 5.1%
vs. normocalcaemic 3.5%; P= 0.43).
The univariate analyses of parameters related to ICH volume are
depicted in supplementary Table A.2 (online only). In multivariable
linear regression model, we found that admission hypocalcaemia was
strongly independently associated with larger ICH volumes (β =11.77,
95% CI 4.66–18.87, P=0.001). The only other variable independently
associated with admission ICH volume in our cohort was older age (age
per year β=0.45, 95% CI 0.16–0.74, P= 0.002), Table 2. Multi-
variable linear regression analysis using calcium as continuous variable
also demonstrated an inverse relationship (β=−87.72, 95% CI
-138.58- -36.86, P=0.001) between increasing serum calcium level
and baseline haematoma volume shown in supplementary Table A.3
(online only).
In unadjusted analysis, three-month mortality was significantly
higher among hypocalcaemic patients than in normocalcaemic patients
(53.1% vs. 34.5%; P < 0.001). The univariate analyses of factors re-
lated to 3-month mortality are listed in supplementary table A.4 (online
only). In the multivariable logistic regression model hypocalcaemia was
not associated with mortality (OR 0.69, 95% CI 3.58–12.96, P=0.13)
after adjusting for known predictors of mortality including haematoma
volume (Table 3). The variables independently associated with mor-
tality were older age (age per year OR 1.04, 95% CI 1.02–1.06,
P < 0.001), larger ICH (OR 1.03, 95% CI 1.02–1.04, P < 0.001) and
IVH (OR 1.04, 95% CI 1.03–1.06, P < 0.001) volumes, and infra-
tentorial location of ICH (OR 6.81, 95% CI 3.58–12.96, P < 0.001),
Table 3.
4. Discussion
We have demonstrated that a significant portion of acute ICH pa-
tients (~40%) were hypocalcaemic, and that a clear association existed
between hypocalcaemia and larger admission ICH volumes. The hy-
pocalcaemic patients had higher 90-day mortality, which was likely
mediated through larger ICH volumes.
Hypocalcaemia has been shown to be common among critically ill
patients, and to associate with higher mortality [21]. The proposed
causes of hypocalcaemia in critically ill patients include catecholamine-
mediated translocation of plasma calcium into tissues and increased
faecal and/or urinary calcium excretion, and hyperadraenergic state
has been shown to be associated with calcium derangement [21]. Thus,
hypocalcaemia may be a reflector of poor outcome in critically ill pa-
tients. However, in our cohort, hypocalcaemia was not independently
associated with mortality. This was not unexpected because the hae-
matoma volume was included in the same model. Hypocalcaemia was
strongly and independently associated with larger ICH volume, which
belongs to most important predictors of mortality among ICH patients.
Previous studies have reported an association between hypo-
calcaemia with larger ICH volumes [16,17]. In a cohort of 273 patients,
the patients were divided in quartiles according to their calcium levels.
The median ICH volume in the lowest serum calcium quartile (≤
2.25mmol/L) was significantly higher (P= 0.005), whereas in all other
groups the ICH volumes were similar [16]. There was no significant
association between hypocalcaemia and mortality after adjustment
with NIHSS and hematoma volume [16]. Morotti et al. reported larger
baseline ICH volume in hypocalcaemic patients (37mL (IQR 15–72mL)
when compared with nomocalcaemic patients (16mL (IQR 6–44mL),
P < 0.001) in 2103 ICH patients but the authors did not report out-
come analysis [17]. In another study of 365 ICH patients the ICH vo-
lumes in different quartiles of serum calcium did not significantly differ
between hypo-, normo- and hypercalcaemic patients, but hy-
percalcaemic (serum calcium ≥2.32mmol/L) patients had better out-
come [18]. Finally, Liotta et al. reported in 290 ICH patients that lower
serum magnesium level on admission was associated with larger hae-
matoma volumes, which suggests that magnesium levels may play a
pathophysiologic role in the haemostasis of ICH patients [22]. In that
study, admission calcium was not significantly associated with ICH
volume or expansion.
In our study, the proportion of hypocalcaemic patients (39.8%) was
higher compared to previously published studies (10.9% [17], 22.7% in
the lowest quartile [16], and 24.7% in the lowest quartile [18]). In
those studies, however, total serum calcium levels were used, or, ad-
ditionally, ionized calcium was used as a continuous variable [17].
Thus, the proportion of hypocalcaemic patients is not fully comparable
with our data.
The effect of calcium on coagulation and association with blood
pressure have been suggested as potential mechanisms for larger ICH
volumes in earlier studies. However, in an earlier study, the hypo-
calcaemic patients did not have significantly higher blood pressure
compared to normocalcaemic patients [17]. In our study, the admission
blood pressures did not differ significantly among hypo- and normo-
calcaemic patients. It has also been suggested that hypocalcaemia
might reflect poor liver function, as one of the studies found that liver
disease was more common among hypocalcaemic ICH patients [16].
However, in our cohort, liver disease was not significantly more
common among hypocalcaemic patients. In our study, age, ICH and IVH
volumes and infratentorial location were independent predictors of
mortality, which is in line with earlier studies [2]. Apart from dyslipi-
daemia, the medical history was similar among hypo- and normo-
calcaemic patients (supplementary Table A.1). In a study on the effect
of hypocalcaemia on coagulation, calcium had a concentration-depen-
dent association with in vitro clot strength after adjusting for other
coagulation abnormalities [23]. In bleeding trauma patients receiving




447 Patients with calcium within 
12 hours of CT
505 Patients with CT within 72 
hours of symptom onset
512 Patients with calcium within 
72 hours of ICH
1013 Patients with diagnosis of 
ICH
Fig. 1. Cohort selection flow chart.
Abbreviations: ICH: intracerebral haemorrhage; CT: computed tomography
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concentration-dependent relationship with mortality [24], and hypo-
calcaemia has been thought to be one of the factors altering haemos-
tasis, and contributing to morbidity and mortality of bleeding patients
in that setting [25].
It has been shown in animal models that ischaemia in neurons leads
to prolonged calcium influx into the cells from extracellular sources
[26]. In an experimental model of ICH in cats, there was a depletion of
calcium ions in the extracellular space, and the calcium levels did not
return to the baseline level. The ionic movement also took place in cells
not directly damaged [27], suggesting a relationship between en-
dothelial dysfunction and hypocalcaemia. As the prior-ICH calcium
levels are not known, we cannot rule out the neuronal damage itself
having an effect on blood calcium levels after the ictus, or that hypo-
calcaemic patients having larger ICH volumes would have a larger
amount of calcium-ions being drawn from the blood to the larger he-
matoma and the surrounding penumbra. Also, as factors related to
Table 1
Characteristics of the patients and comparison of radiological parameters, SMASH-U classification, laboratory test results, and outcome parameters between hy-
pocalcemic and normocalcemic patients.
Variable Hypocalcemic patients
(n=178)
Normocalcemic patients (n= 255) P value Missing values hypocalcemia/
normocalcemia
Age in years 62.0 (57–71) 65.0 (57–76) 0.12 0/0
Male 119 (66.9) 145 (56.9) 0.04 0/0
Pre-ICH mRS 3–5 8 (4.5) 13 (5.1) 0.77 0/0
Comorbidities
Hypertension 161 (63.1) 109 (61.2) 0.69 0/0
Diabetes 28 (15.7) 39 (15.3) 0.9 0/0
Dyslipidaemia 23 (13.3) 55 (21.7) 0.03 5/1
History of ischemic stroke 21 (11.8) 27 (10.6) 0.69 0/0
History of ICH 8 (4.5) 8 (3.1) 0.46 0/0
Liver disease 6 (3.5) 8 (3.1) 0.85 6/1
Coronary artery disease 19 (11.0) 26 (10.3) 0.80 6/2
Atrial fibrillation 19 (10.7) 33 (12.9) 0.48 0/0
Epilepsy 5 (2.9) 10 (3.9) 0.56 5/1
Medications prior to ICH
Antiplatelets 41 (23.0) 56 (22.0) 0.81 0/1
Oral anticoagulants 18 (10.1) 34 (13.3) 0.31 0/0
Statins 22 (12.9) 50 (19.9) 0.059 7/4
Antihypertensives 75 (42.1) 123 (48.2) 0.21 0/0
Clinical admission parameters
NIHSS 19.0 (10.0–34.0) 12.0 (6.0–21.0) <0.001 0/0
GCS 10.0 (4.0–14.0) 14.0 (10.0–15.0) <0.001 0/0
Systolic blood pressure, mmHg 175.6 (2.91) 172.2 (2.26) 0.35 17/28
Diastolic blood pressure, mmHg 94.6 (1.93) 91.7 (1.38) 0.17 17/31
Time from ICH onset to baseline CT, hours 3.5 (1.6–9.8) 2.1 (1.4–4.8) 0.002 0/0
Radiological parameters on admission CT
ICH volume, mL 30.2 (11.4–58.7) 16.8 (7.4–44.2) <0.001 0/0
Oedema volume, mL 18.0 (6.6–37.2) 11.6 (5.6–30.4) 0.11 0/0
IVH volume, mL 2.9 (0.0–22.5) 0.0 (0.0–8.7) <0.001 0/0
ICH location 0.14 0/0
Lobar 54 (30.3) 92 (36.1)
Deep 91 (51.1) 132 (51.8)
Infratentorial 33 (18.5) 31 (12.2)
Multiple haemorrhages 9 (5.1) 10 (3.9) 0.571 0/0
SMASH-U classification 0.21 0/0
Amyloid angiopathy 23 (12.9) 48 (18.8)
Hypertension 74 (41.6) 92 (36.1)
Medication 22 (12.4) 36 (14.1)
Other disease 11 (6.2) 12 (4.7)
Structural lesion 4 (2.2) 14 (5.5)
Undetermined 44 (24.7) 53 (20.8)
Admission laboratory results
Haemoglobin, g/L 138.1 (1.4) 138.5 (1.1) 0. 93 3/3
White cell count, 109/L 9.7 (7.2–12.0) 8.0 (6.4–10.4) <0.001 2/3
Platelet count, 109/L 211.1 (6.2) 213.6 (4.1) 0.53 6/4
CRP, mg/dL 5.0 (3.0–7.0) 4.0 (3.0–6.0) 0.017 2/2
INR 1.0 (1.0–1.2) 1.0 (0.9–1.2) 0.500 33/49
Glucose on admission or in ambulance, mmol/
L
8.4 (6.9–10.8) 7.5 (6.3–9.5) <0.001 1/1
Potassium, mmol/L 3.7 (3.3–4.0) 3.8 (3.5–4.1) 0.018 6/5
Sodium, mmol/L 137.0 (135.0–139.0) 138.0 (136.0–140.0) 0.046 5/5
Creatinine, μmol/L 63.0 (54.0–82.5) 69.0 (58.0–85.8) 0.040 9/7
Any neurosurgery 28 (15.7) 31 (12.2) 0.29 0/0
90-d-Mortality 93 (53.1) 87 (34.5) <0.001 3/3
ICH: intracerebral haemorrhage; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; GCS: Glasgow Coma Scale; CT: computed tomo-
graphy; IVH: intraventricular haemorrhage; SMASH-U classification: etiologic classification of ICH; CRP: C-reactive protein.
Data are presented as number of patients with percentages in parentheses, median with interquartile ranges in parentheses, and mean with standard error in
parentheses.
Bold is P value< 0.05.
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possible pre-ICH hypocalcaemia, such as vitamin D, and parathyroid
hormone levels, are not known, we cannot rule out these underlying
states itself affecting the haematoma volume.
The association between hypocalcaemia and ICH volume is likely
mediated through the negative influence of hypocalcaemia on coagu-
lation. The higher mortality rates seen in hypocalcaemic patients is
likely to be accounted for by larger ICH volume which is one of the most
powerful predictors of mortality [2].
The strengths of our study are utilization of planimetry methods,
and consecutive character of the cohort. We used the ionized calcium
level, which reflects better the physiologically active calcium [28]. For
obtaining the most relevant values, we limited the timing of the la-
boratory test to 12 h from the admission CT and both brain CT and
ionized calcium measurements to 72 h of symptom onset. The majority
of patients were admitted within the first hours after the ictus (Sup-
plemental Fig. A.1).
The limitations of our study stem from its retrospective nature. We
also had a large proportion of patients with missing early calcium va-
lues. The possible selection bias for analysing calcium for certain pa-
tients could not be out ruled. The timing of the CT and blood samples in
relation to symptom onset varied, limiting our ability to evaluate a
potential relationship between calcium levels and ICH growth. As the
median time from ICH onset to CT was longer (median 3.5 h, IQR
1.6–9.8 vs. 2.1 h, IQR 1.4–4.8; p= 0.002) in the hypocalcaemic group,
we cannot rule out the time itself having some effect on ICH volume;
however, in linear multivariate analysis, time was not an independent
predictor on ICH volume. Due to the acute nature of the illness, many
patients are expected to have received intravenous fluids already before
arriving to hospital, before laboratory testing. However, the amount of
such fluid intake could not be evaluated retrospectively, which is the
main reason for applying our inclusion criteria, i.e. the maximum time
delayed allowed between ICH onset and laboratory testing. Finally we
were unable to examine the association between hypocalcaemia and
functional recovery as follow up was not routine at our institution
during the study period. Mortality however is a robust endpoint and
information on mortality was derived from a reliable source.
In future, prospective clinical studies could be planned to take into
consideration and overcome some of the limitations of our study. The
blood samples could be collected as early as possible, and preferably
before intravenous fluid administration. To find out the possible causes
for hypocalcaemia, more extensive laboratory testing, including vi-
tamin D, and parathyroid hormone could be done, as well as repeated
sampling of calcium to find out possible changes with time in the face of
acute ICH. Interesting topic would be to investigate, if correction of
hypocalcaemia in ICH patients affects their prognosis.
5. Conclusion
Admission hypocalcaemia among ICH patients was associated with
larger ICH volumes, and hypocalcaemic patients had higher 90-day
mortality than normocalcaemic patients (53.1% vs. 34.5%), which was
driven by larger ICH volumes in hypocalcaemic patients. Larger pro-
spective studies are needed to further examine the relationship between
serum calcium and ICH volume.
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